PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: FR0010259150; IPN) (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced an agreement whereby Ipsen grants the Menarini Group the exclusive licence rights to Adenuric® (febuxostat) in 41 countries. Ipsen retains co-promotion rights for Adenuric® in France. With its significant pan-European presence, Menarini ranks fourth largest pharmaceutical team for delivering medical information to physicians. Adenuric® received marketing authorisation in the European Union on 21st April 2008. Its 80 mg and 120 mg tablets are indicated for the treatment of chronic hyperuricaemia for conditions in which urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). In 2003, Teijin Pharma Limited, Tokyo who discovered febuxostat had granted Ipsen the exclusive development and marketing rights to Adenuric® in Europe.
